Article Figures & Data
Figures
- Figure 1.
Kaplan-Meier curve of the loss of remission during treatment with anti-TNF agents in 174 patients with axial spondyloarthritis. Anti-TNF: antitumor necrosis factor.
- Figure 2.
Kaplan-Meier curves of the loss of response of ADA, ETN, and IFX in 174 patients with axial spondyloarthritis. ADA: adalimumab; ETN: etanercept; IFX: infliximab.
Tables
- Table 1.
Demographic, clinical, and laboratory features of the patients with axSpA (n = 174) in remission and under treatment with TNF-α blockers. The measures of disease activity are the median values of the remission period. Values are median (IQR) or n (%) unless otherwise specified.
Variables Values Male/female, n 133/41 Age, yrs, mean (SD) 43.2 (12.7) Disease duration, yrs 7 (3–14) Presence of HLA-B27 122 (70.1) CRP, mg/dl 0.3 (0.1–0.5) ESR, mm/h 9 (4–13.75) BASDAI 1.6 (0.9–2.4) BASMI 2 (0–3) BASFI 1.5 (0.7–2.4) PtGA, cm 1.2 (0.5–2) VAS physician, cm 0.5 (0–1.5) VAS back pain, cm 1.3 (0.4–2) ASDAS-CRP 1.1 (0.6–1.5) Presence of grade IV sacroiliitis 44 (25.2) Presence of psoriasis 18 (10.3) Presence of IBD 20 (11.4) Presence of uveitis 23 (13.1) Therapy NSAID, continuous 21 (12.1) sDMARD 25 (14.3) IFX 102 (58.6) ADA 25 (14.3) ETN 47 (27.1) axSpA: axial spondyloarthritis; TNF-α: tumor necrosis factor-α; IQR: interquartile range; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; PtGA: patient’s global assessment; VAS: visual analog scale; ASDAS: Ankylosing Spondylitis Disease Activity Score; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drugs; sDMARD: synthetic disease-modifying antirheumatic drugs; IFX: infliximab; ADA: adalimumab; ETN: etanercept.
- Table 2.
Association of main demographic and clinical variables with loss of remission and disease flare in patients with axSpA in remission with anti-TNF-α therapy. Values are median (IQR) or n (%) unless otherwise specified.
Variables Loss of Remission Disease Flare Yes, n = 37 No, n = 137 p Yes, n = 28 No, n = 146 p Male vs female 28 (75.7) 105 (76.6) 0.902 22 (78.6) 111 (76) 0.771 Age, yrs, mean (SD) 44.1 (13.5) 43.1 (12.6) 0.699 44.2 (13.9) 43.1 (12.5) 0.662 Disease duration, mos 108 (36–192) 82 (36–155) 0.289 88 (36–153) 84 (36–168) 0.732 ESR, mm/h 12 (10–19) 7 (4–12) 0.001 12 (9–19) 7 (4–13) 0.001 CRP, mg/dl 0.5 (0.2–0.6) 0.2 (0.03–0.5) 0.010 0.5 (0.2–0.6) 0.2 (0.05–0.5) 0.022 NSAID, concomitant use vs sporadic use 9 (24.3) 12 (8.9) 0.011 8 (28.6) 13 (9) 0.004 HLA-B27, presence vs absence 28 (75.7) 94 (68.6) 0.405 21 (75) 101 (69.2) 0.538 ASDAS-CRP 1.22 (0.88–1.62) 0.98 (0.42–1.51) 0.107 1.28 (0.91–1.65) 0.99 (0.42–1.51) 0.056 ASDAS-CRP > 0.8 vs ≤ 0.8 29 (78.4) 78 (57.8) 0.022 23 (82.1) 84 (58.3) 0.017 EAM, presence vs absence 12 (32.4) 43 (31.4) 0.903 9 (32.1) 46 (31.5) 0.947 axSpA: axial spondyloarthritis; TNF-α: tumor necrosis factor-α; IQR: interquartile range; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; NSAID: nonsteroidal antiinflammatory drugs; ASDAS: Ankylosing Spondylitis Disease Activity Score; EAM: extraarticular manifestations.
- Table 3.
Association of main demographic and clinical variables with loss of remission and disease flare in patients with axSpA in remission while taking anti-TNF-α therapy (logistic regression).
Variables Loss of Remission Disease Flare OR 95% CI p OR 95% CI p Age, yrs 1.005 0.970–1.041 0.780 1.014 0.976–1.054 0.463 Male vs female 0.797 0.301–2.110 0.648 1.089 0.348–3.407 0.883 Disease duration, mos 1.002 0.998–1.006 0.278 1.000 0.995–1.005 0.947 IFX vs ADA + ETN 1.034 0.410–2.606 0.943 1.192 0.420–3.383 0.741 ADA vs IFX + ETN 1.152 0.294–4.515 0.839 1.250 0.267–5.840 0.777 ESR, > 15 vs ≤ 15 2.901 1.233–6.824 0.015 2.691 1.044–6.937 0.040 NSAID continuous use 4.054 1.400–11.738 0.010 4.540 1.532–13.454 0.006 axSpA: axial spondyloarthritis; TNF-α: tumor necrosis factor-α; IFX: infliximab; ADA: adalimumab; ETN: etanercept; ESR: erythrocyte sedimentation rate; NSAID: nonsteroidal antiinflammatory drugs.
